Author:
Korotych Oleksandr,Achar Jay,Gurbanova Elmira,Hovhannesyan Arax,Lomtadze Nino,Ciobanu Ana,Skrahina Alena,Dravniece Gunta,Kuksa Liga,Rich Michael,Khachatryan Naira,Germanovych Myroslava,Kadyrov Abdullat,Terleieva Iana,Akhundova Irada,Adenov Malik,Durdyeva Myahri,Kiria Nana,Parpieva Nargiza,Yatskevich Natalia,Jumayev Rovshen,Nurov Rustam,Diktanas Saulius,Vilc Valentina,Migliori Giovanni Battista,Yedilbayev Askar
Reference19 articles.
1. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis;Sotgiu;Eur Respir J,2016
2. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study;Ndjeka;Lancet Infect Dis,2022
3. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea
4. A 24-week, all-oral regimen for rifampin-resistant tuberculosis;Nyang'wa;N Engl J Med,2022
5. The use of BPaL-containing regimen in the MDR/preXDR TB treatments in Thailand;Sangsayunh;J Clin Tuberc Other Mycobact Dis,2023